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treated only with radiotherapy- 7 patients- 13.2 %, combined treatment- 6 patients- 11,3%. 
Chemotherapy treatment consists of complex treatment regimens containing at least 2 
chemotherapeutic preparations. The patients has be treated with fluorouracil, doxorubicin, 
cisplatin, cyclophosphamide .We can mention that fluorouracil was used by 28 patients, 
doxorubicin-24, cisplatin -30, cyclophosphamide-14.   
Conclusions.  Treatment for metastatic cancer aims to slow the growth or spread of the cancer. 
The treatment depends on the type of cancer, where it started, the size and location of the 
metastasis, and other factors. Even if metastatic cancer has stopped responding to treatment, 
many therapies may help ease side effects and improve quality of life.   
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Introduction. Breast cancer is the most common cancer diagnosed in women worldwide, with 
nearly 1.7 million new cases diagnosed annually (25% of the total) and 571,000 deaths. In 
Europe, breast cancer accounts for the highest share (26.4%) of all cancers in women, with 
522,513 new cases, far above colon cancer (11.5%; 228,067 new cases) and lung cancer (8%; 
158,196 new cases). The incidence of breast cancer in Moldova in 2018 was 1125, and the 
morbidity was 360.6 per 100 thousand population.  
Aim of the study. This study aims to analyze the clinical evolution and treatment of breast 
cancer at different stages in young women.   
Materials and methods.. The study is based on a retrospective descriptive analysis carried out 
for about 3 years. The group included 63 patients, all women between the ages of 24 and 45, 
diagnosed with breast cancer at various stages. Clinical evolution, stage, tumor size, 
preoperative treatment and surgical method were evaluated.  
Results. We found that of 63 patients, 61 had clinical symptoms, while 2 patients were 
diagnosed during screening. The complaints of the patients included palpation of a hard, 
immobile, painless tumor of irregular outline – 50 cases (82%); breast swelling – 8 cases 
(13%); nipple leaks – 2 cases (3%), pain – 1 case (2%). Tumor sizes ranged from 1.0 cm to 5.5 
cm. Thirty-eight patients had tumors smaller than 2 cm, 24 patients had tumors with sizes 
between 2 and 5 cm and 1 patient had tumor of 5.5 cm. There were diagnosed 3 patients (5%) 
with stage I; 13 patients (21%) with stage IIA; 39 patients (62%) with stage IIB; 4 patients 
(6%) with stage IIIA; 4 patients (6%) with stage IIIB. Out of 63 patients, 42 patients (67%) 
received preoperative treatment: chemotherapy – 39 patients (61.9%), radiotherapy – 3 patients 
(4.7%). Of the patients receiving chemotherapy, 5 patients took 2 courses, 16 patients – 3 
courses, 14 patients – 4 courses, 2 patients – 6 courses, 2 patients – 8 courses. Surgical 
treatment of malignancies was performed by two methods: single mastectomy – 18 malignant 
tumors (28.5%), Madden radical mastectomy – 45 malignant tumors (71.5%).  
Conclusions. We found that of 63 patients, 61 had clinical symptoms, while 2 patients were 
diagnosed during screening. The complaints of the patients included palpation of a hard, 
immobile, painless tumor of irregular outline – 50 cases (82%); breast swelling – 8 cases 
The 8th International Medical Congress for Students and Young Doctors 
 ____________________________________________________________________________________ 
91 
 
(13%); nipple leaks – 2 cases (3%), pain – 1 case (2%). Tumor sizes ranged from 1.0 cm to 5.5 
cm. Thirty-eight patients had tumors smaller than 2 cm, 24 patients had tumors with sizes 
between 2 and 5 cm and 1 patient had tumor of 5.5 cm. There were diagnosed 3 patients (5%) 
with stage I; 13 patients (21%) with stage IIA; 39 patients (62%) with stage IIB; 4 patients 
(6%) with stage IIIA; 4 patients (6%) with stage IIIB. Out of 63 patients, 42 patients (67%) 
received preoperative treatment: chemotherapy – 39 patients (61.9%), radiotherapy – 3 patients 
(4.7%). Of the patients receiving chemotherapy, 5 patients took 2 courses, 16 patients – 3 
courses, 14 patients – 4 courses, 2 patients – 6 courses, 2 patients – 8 courses. Surgical 
treatment of malignancies was performed by two methods: single mastectomy – 18 malignant 
tumors (28.5%), Madden radical mastectomy – 45 malignant tumors (71.5%).  
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Introduction. Borderline ovarian tumors are a special group of tumors that have 
histopathological character and lie between benign and malignant ovarian tumors. 15 to 25 % 
of gynecological tumors are borderline ovarian tumors, whereas serous and mucosal tumors in 
the histological majority are borderline affecting the reproductive age. Borderline ovarian 
tumors or semi-malignant tumors are a group of lesions that show some malignant character 
(moderate cellular atypia, epithelial stratification, reduced mitotic activity), but without stromal 
invasion.  
Aim of the study. The purpose of this paper is to present the statistical results and to analyze 
the data from  the published literature concerning this pathology with respect to the surgical 
and  chemotherapeutic treatment of borderline ovarian tumors.  
Materials and methods.. The retrospective study was performed with a group of 40 patients 
who are suffering  from tumors with low-malignancy and a good long-term prognosis. Surgical 
treatment is the fundamental treatment of borderline ovarian tumors, but there are some debates 
concerning  chemotherapeutical treatment.  
Results. După structura istologică, în ovarienă tumorală se limitează la un punct tipic seros 
prevalent în 64%,  urmat de mucinoase cu 31% și tipul endometroid i-au revenit 5%.  
Diagnosticul intraoperator al tumorilor ovariene de frontieră s-a bazat pe: concreșteri  
papilomatoase în 31 de timp cu 78%, ruperea capsulei tumorii depistată la 5 paciente ce a  
constituie 14%, afectarea bilaterală ovariană la 17 paciente (47%), ascendentă în 6 poate cu 
16,6%.  
Conclusions. According to the histological structure, in the borderline ovarian tumors the 
serous type prevailed in 64%,  followed by mucinous 31% and endometroid type took up 5%.  
The intraoperative diagnosis of borderline ovarian tumors was based on: findings  
papillomatous in 31 cases with 78%, tumor capsule rupture detected in 5 patients who  
constituted 14%, bilateral ovarian involvement in 17 patients (47%), ascites in 6 cases with 
16.6%.  
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